Francisco Javier Díaz de Teran Velasco
Francisco Javier Díaz de Teran Velasco
Neurologist Specialist
Neurologíaen/specialities/neurologia
See more specialists on
Madridmadrid
en/medical-staff/neurologist
Dr. Francisco Javier Díaz de Terán Velasco is a distinguished neurologist and holds a Doctorate in Medicine and Surgery from the Universidad Autónoma de Madrid, where he graduated with highest honors (Cum Laude) in 2021. He currently practices as a neurology specialist at the Centro de Alto Rendimiento Olympia in Madrid. Among his most significant scientific contributions is the article "Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study," published in the journal *J Headache Pain* in November 2025. His professional excellence has been recognized with the 2026 Scientific Award in Headache from the Spanish Society of Neurology , in honor of his scientific, clinical, and educational career. He is also an active member of the Madrid Association of Neurology , reinforcing his commitment to the advancement of the specialty.
Key information
- Scientific Award in Headaches 2026 from the Sociedad Española de Neurología, in recognition of his scientific, care and training career.2026
- Latest Publication:Cluster headache, beyond the pain: a comparative cross-sectional study
- Belongs to:Grupo de Cefaleas de la AMN
Professional Details
Centro médico-quirúrgico Olympia
SPECIALIST PHYSICIAN NEUROLOGY
December 2021
Hospital Universitario La Paz
Neurologist
May 2016
Study
Bachelor of Medicine
university, Universidad de Navarra
2010
Doctorate
Universidad Autónoma de Madrid
2021
Specialized Healthcare Training
Neurology Specialist
hospital
Another qualification
Specialized Medical Training Program in Neurology
government
Another qualification
Training rotation in headaches
hospital
Another qualification
International training program on headaches
international
Another qualification
Training rotation in the Epilepsy Unit
hospital
Regular speaker at training courses and meetings of various scientific societies
Universidad Francisco de Vitoria
Master's degree in headaches
Universidad Francisco de Vitoria
Courses on migraine and neuropathic pain
Universidad Autónoma de Madrid (UAM)
Continuing medical education in various neurological pathologies
Headache Residents' Course
Asociación Madrileña de Neurología
Spanish Pain Society (SED)
Professional Master's Degree in Pain Medicine
Sociedad Española del Dolor
Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks: Interventional randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of migraine in patients with a dual diagnosis of migraine and Medication Overuse Headache
A Multicenter Randomized, Double-Blind, Parallel-Group Study Evaluating the Long Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
ALDA03.CLIN-011: Parallel, double-blind, randomized, placebo-controlled Phase 3 trial to evaluate the efficacy and safety of ALDA03 administered Intravenously in patients with chronic migraine
TRIUMPH Study: preventive Treatment of migraine: outcomes for Patients in real-world Healthcare systems
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age
A 12-month prospective, randomized, interventional global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab vs oral prophylactic) in adult episodic migraine patients
Phase 4 randomized, double-blind placebo controlled study to evaluate the efficacy and safety of Rimegepant in episodic migraine prevention with multiple dosing regimen
OnabotulinumtoxinA in high frequency episodic migraine
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 versus Placebo for the Preventive Treatment of Chronic Migraine
Phase 2 multicenter, double-blind run-in phase followed by a 12-week, prospective, parallel-group, double-blind, randomized withdrawal placebo-controlled study, with a 52 week open label extension, to evaluate the efficacy and safety of daily 15 to 3.5 mg basimgurant in patients with pain associated with trigeminal neuralgia with suboptimal response to their current anti-pain therapy
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 versus Placebo for the Preventive Treatment of Episodic Migraine
SIA phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between Clobazam and Cannabidiol (CWVP42003-P)
Cluster headache, beyond the pain: a comparative cross-sectional study
Journal Article
Headache as a Cardinal symptom of Coronavirus Disease 2019: A Cross Sectional Study
Journal Article
Impact of Greater Occipital Nerve Block on Photophobia Levels in Migraine Patients
Journal Article
Migraine review for general practice
Journal Article
Occipital Nerve Stimulation for Pain Modulation in Drug-resistant Chronic Cluster Headache
Journal Article
Persistent headache after COVID-19: Pathophysiology, clinic and treatment
Journal Article
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
Journal Article
Refractory clusteric syndrome: The Hikams dictum
Journal Article
HaNDL Syndrome: A Review
Journal Article
The Triptans Hangover: A Multicentric Cross-sectional Observational Study of the Adverse Events of Triptans in Patients With Migraine
Journal Article
Grupo de Cefaleas de la AMN
Instituto de investigación del Hospital Universitario La Paz
Asociación Madrileña de Neurología
International Headache Society
Sociedad Española de Neurología
Grupo de Estudio de Cefalea de la SEN
European Academy of Neurology
Scientific Award in Headaches 2026 from the Sociedad Española de Neurología, in recognition of his scientific, care and training career.
Sociedad Española de Neurología
Finalist in the 2025 Healthcare Leadership Awards in Neurology
Liderazgo Sanitario
Principal Investigator of the project funded by the Instituto de Salud Carlos III (PI24/01254, 2025-2028), focused on cluster headache
Instituto de Salud Carlos III (Ministerio de Sanidad)
Make an appointment with this professional
